Frameworks for Digital Advertising
Standards in Medicine.

United States · Advertising framework

Email, SMS and direct-message marketing for diagnostic tests and services in the United States

General market orientation, not campaign clearance. Research scope and dates

Product and service rules

Check the actual device status and advertising jurisdiction

Regulator guidance

Do not equate establishment registration, 510(k) clearance and premarket approval. Restricted-device advertising has specific information and misleading-advertising controls. Assess the exact device, authorised purpose and whether an advertised testing offer is also a clinical service.

Sources: General Controls for Medical Devices

Match the evidence to the precise advertised benefit

Regulator guidance

Applies when: The claim falls within FTC health-advertising oversight; FDA product-specific requirements also need review.

FTC guidance generally expects randomised controlled human clinical testing for health-benefit claims, with design and quality appropriate to the claim and the scientific field. Animal studies or consumer anecdotes alone do not establish human benefits.

Assess the actual formulation, dose, population and outcome. An ingredient study or a clinically tested claim must not imply a proven finished-product effect that the evidence does not support.

Sources: FTC Health Products Compliance Guidance · FTC Health Products Compliance Guidance, substantiation and amount/type of evidence

Channel rules

Review implied claims as well as literal wording

Regulator guidance

FTC guidance assesses the overall impression of health advertising. Hold appropriate scientific evidence before publication; an honest testimonial does not substitute for evidence of the advertised result. Treat imagery and omitted qualifications as part of that assessment.

Sources: FTC Health Products Compliance Guidance

Commercial email follows CAN-SPAM; SMS needs its own review

Regulator guidance

CAN-SPAM requires accurate sender and subject information, advertising identification as applicable, a postal address and a clear opt-out. Honour opt-outs within ten business days. It is not a general prior-consent requirement for all commercial email and does not determine the separate TCPA or state rules for marketing texts.

Sources: CAN-SPAM Act: A Compliance Guide for Business

Analyse marketing calls and texts separately from email

Regulator guidance

For calls and texts covered by the TCPA, identify the calling technology, message purpose, recipient number and any exemption. Covered telemarketing generally requires prior express written consent; CAN-SPAM compliance does not supply it. Preserve consent evidence and an effective revocation process. The 2024 order is not a complete statement of later implementation dates: check subsequent FCC orders, litigation and state rules before approving a live SMS programme.

Sources: TCPA consent and revocation order

Washington health data may be regulated outside HIPAA

Regulator guidance

Applies when: Processing within the scope of Washington’s My Health My Data Act.

Where Washington’s My Health My Data Act applies, collection generally needs purpose-specific consent unless necessary for a requested product or service; sharing requires a distinct consent unless the necessary-service exception applies. Review applicability and exemptions by data and activity, rather than assuming HIPAA status clears advertising tracking. Regulated entities must prominently link a separate consumer health data privacy policy from the homepage.

Sources: Washington consumer-health-data collection and sharing; My Health My Data Act — scope and FAQ

Separate promotional and service messages

Editorial recommendation

Review the rules for the actual delivery method: email, SMS and private social messages are not interchangeable. Keep the relevant permission record, accurate sender details and a working suppression process.

Campaign workflow

Diagnostics & Health Testing: prepare the review

Editorial recommendation

Separate a test kit, laboratory service, screening package and medical interpretation. State the intended population and explain the limits of a positive or negative result. Review both product rules and provider rules when a device is bundled with a clinical service.

Keep a traceable campaign decision

Editorial recommendation

Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.

Pre-publication checklist

  • Separate a test kit, laboratory service, screening package and medical interpretation.
  • State the intended population and explain the limits of a positive or negative result.
  • Review both product rules and provider rules when a device is bundled with a clinical service.
  • Record product or provider eligibility before approving claims.
  • Archive the final creative and its evidence, permissions and review decisions.
  • Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.

Scope and unresolved questions

  • California physician telehealth and Washington consumer-health-data requirements are now documented as scoped examples. Other state medical/dental/pharmacy rules, corporate practice, fee splitting, referral arrangements and state telemarketing laws remain to be assessed for the actual provider and patient location.
  • FDA television/radio-format standards and a scoped Washington health-data rule are documented. Exact TCPA revocation implementation dates and post-litigation consent text were not fully verified from accessible primary documents; final SMS clearance remains open. Platform, broadcaster and other state rules depend on the actual execution.
Research scope, introduction and dates

Advertising diagnostic tests and services by email, SMS and direct messages in the United States requires a distinction between the test product, the laboratory service and the interpretation of the result. Use this framework to review those layers and the limits of the advertised outcome.

Email, SMS and private platform messages can follow different permission rules. Identify the delivery technology and the recipient relationship, then review the promotional content and withdrawal process separately.

Sources checked 2026-10-24 · Editorial research · Legal review pending

General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.

Coverage: National baseline and category-specific review routes; not an exhaustive compliance opinion

How to use this national baseline

Editorial overview

This framework combines researched national rules with editorial review steps. Federal advertising baseline; state professional, pharmacy and privacy rules require a separate review. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.

The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.

Your next step: choose a local partner

Use this framework to brief qualified local legal and regulatory specialists. Ask them to verify current requirements and assess your specific product, service and campaign before acting.

Sources

  1. General Controls for Medical Devices

    FDA · regulator guidance · checked 2026-10-24

    Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.

  2. FTC Health Products Compliance Guidance

    Federal Trade Commission · regulator guidance · checked 2026-10-24

    Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.

  3. CAN-SPAM Act: A Compliance Guide for Business

    Federal Trade Commission · regulator guidance · checked 2026-10-24

    Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.

  4. My Health My Data Act — scope and FAQ

    Washington Attorney General · regulator guidance · checked 2026-10-25

    Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.

From framework to action

Local expertise in United States

Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in United States.

Medical & health marketing

No partners listed in this category yet.

Marketing & sales advisory

No partners listed in this category yet.

Business & project coordination

No partners listed in this category yet.

Browse partners in United States

Join the local partner directory

Would you like your company to be listed?

Talk to us about the terms of a listing. Leave your details and we will get in touch.

Publicity@fdasm.com

Contact details for a partner listing enquiry

We use your details to respond to your enquiry and discuss a listing. Submitting the form does not automatically add your company to the directory. Read our Privacy & cookies policy. Privacy contact: Publicity@fdasm.com.